Today XVIVO Perfusion AB (publ) publish the Annual Report for 2020. The Annual Report is attached to this press release in pdf format and in ESEF format (European Single Electronic Format) and is also available on www.xvivoperfusion.com.
A printed version of the Annual Report 2020 can be ordered by phone +46 (0) 31 788 21 50 or by email info@xvivoperfusion.com.
March 29, 2021
Gothenburg
XVIVO Perfusion AB (publ)
For further information, please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-mail: dag.andersson@xvivoperfusion.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivoperfusion.com
About Us
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden, one office in Groningen, the Netherlands and one office in Denver, USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-03-29 12:35 CEST.